U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H12N2
Molecular Weight 160.2157
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TOLAZOLINE

SMILES

C(C1=NCCN1)C2=CC=CC=C2

InChI

InChIKey=JIVZKJJQOZQXQB-UHFFFAOYSA-N
InChI=1S/C10H12N2/c1-2-4-9(5-3-1)8-10-11-6-7-12-10/h1-5H,6-8H2,(H,11,12)

HIDE SMILES / InChI

Molecular Formula C10H12N2
Molecular Weight 160.2157
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Tolazoline, also known as priscoline, was used in treatment of persistent pulmonary hypertension of the newborn. But that prescription was discontinued. Priscoline given intravenously produces vasodilatation, primarily due to a direct effect on vascular smooth muscle, and cardiac stimulation; the blood pressure response depends on the relative contributions of the two effects. Priscoline usually reduces pulmonary arterial pressure and vascular resistance. The mechanisms of its therapeutic effects are not clear, but is known, that tolazoline is a non-selective competitive α-adrenergic receptor antagonist and it possesses histamine agonist activity.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PRISCOLINE

Approved Use

Unknown

Launch Date

1948
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.8 mg/L
3.2 mg single, intravenous
dose: 3.2 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TOLAZOLINE blood
Homo sapiens
population: UNHEALTHY
age: NEWBORN
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.15 h
3.2 mg single, intravenous
dose: 3.2 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TOLAZOLINE blood
Homo sapiens
population: UNHEALTHY
age: NEWBORN
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Other AEs: Erythema, Thrombocytopenia...
Other AEs:
Erythema (60%)
Thrombocytopenia (45%)
Hyponatremia (40%)
Gastric acid increased (36%)
Seizures (30%)
Hematuria (23%)
Hypotension (19%)
Oliguria (11%)
Abdominal distension (9%)
Activity motor exaggerated (6%)
Tracheal bleeding (6%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Oliguria 11%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Hypotension 19%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Hematuria 23%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Seizures 30%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Gastric acid increased 36%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Hyponatremia 40%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Thrombocytopenia 45%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Activity motor exaggerated 6%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Tracheal bleeding 6%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Erythema 60%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Abdominal distension 9%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[Tolazoline and dopamine in the treatment of the persistent fetal circulation syndrome].
1983 Oct
[Renal disorders in the newborn infant].
1984 Jan-Feb
Bolus and continuous infusion of tolazoline in neonates with hypoxemia.
1986
Nonlocalized lower gastrointestinal bleeding: provocative bleeding studies with intraarterial tPA, heparin, and tolazoline.
2001 Nov
Is nebulised tolazoline an effective treatment for persistent pulmonary hypertension of the newborn?
2003 Jan
Pharmacokinetics of xylazine, 2,6-dimethylaniline, and tolazoline in tissues from yearling cattle and milk from mature dairy cows after sedation with xylazine hydrochloride and reversal with tolazoline hydrochloride.
2003 Summer
2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands.
2004 Sep 20
Antagonism of detomidine sedation in the horse using intravenous tolazoline or atipamezole.
2006 May
A diazonium ion cascade from the nitrosation of tolazoline, an imidazoline-containing drug.
2008 Feb
N-nitrosotolazoline: decomposition studies of a typical N-nitrosoimidazoline.
2008 Feb
A comparison of two combinations of xylazine-ketamine administered intramuscularly to alpacas and of reversal with tolazoline.
2008 May
A novel high-throughput screening assay for putative antidiabetic agents through PPARalpha interactions.
2008 Oct
Evaluation of intramuscular butorphanol, azaperone, and medetomidine and nasal oxygen insufflation for the chemical immobilization of white-tailed deer, Odocoileus virginianus.
2008 Sep
A novel approach for percutaneous treatment of massive nonocclusive mesenteric ischemia: tolazoline and glycerol trinitrate as effective local vasodilators.
2009 Feb 1
Physiologic effects of nasal oxygen or medical air administered prior to and during carfentanil-xylazine anesthesia in North American elk (Cervus canadensis manitobensis).
2009 Mar
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Patents

Patents

Sample Use Guides

In Vivo Use Guide
An initial dose of 1 to 2 mg/kg, via scalp vein, followed by an infusion of 1 to 2 mg/kg per hour have usually resulted in significant increases in arterial oxygen. There is very little experience with infusions lasting beyond 36 to 48 hours. Response, if it occurs, can be expected within 30 minutes after the initial dose.
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:38:36 GMT 2023
Edited
by admin
on Fri Dec 15 16:38:36 GMT 2023
Record UNII
CHH9H12AQ3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TOLAZOLINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
TOLAZOLINE [VANDF]
Common Name English
Tolazoline [WHO-DD]
Common Name English
NSC-35110
Code English
tolazoline [INN]
Common Name English
TOLAZOLINE [MI]
Common Name English
TOLAZINE
Brand Name English
Classification Tree Code System Code
WHO-VATC QM02AX02
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
WHO-VATC QV03AB94
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
WHO-ATC M02AX02
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
WHO-VATC QC04AB02
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
NCI_THESAURUS C29713
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
WHO-ATC C04AB02
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
Code System Code Type Description
WIKIPEDIA
TOLAZOLINE
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
PRIMARY
EVMPD
SUB11148MIG
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
PRIMARY
CAS
59-98-3
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
PRIMARY
EPA CompTox
DTXSID3023683
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
PRIMARY
NSC
35110
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
PRIMARY
DRUG BANK
DB00797
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-448-9
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
PRIMARY
SMS_ID
100000077751
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
PRIMARY
MESH
D014043
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
PRIMARY
MERCK INDEX
m10936
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
PRIMARY Merck Index
NCI_THESAURUS
C66608
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
PRIMARY
IUPHAR
7310
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
PRIMARY
INN
4213
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
PRIMARY
ChEMBL
CHEMBL770
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
PRIMARY
FDA UNII
CHH9H12AQ3
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
PRIMARY
DAILYMED
CHH9H12AQ3
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
PRIMARY
PUBCHEM
5504
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
PRIMARY
RXCUI
10634
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
PRIMARY RxNorm
DRUG CENTRAL
2695
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
PRIMARY
CHEBI
28502
Created by admin on Fri Dec 15 16:38:36 GMT 2023 , Edited by admin on Fri Dec 15 16:38:36 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
TARGET -> AGONIST
SHORT-ACTING
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY